This prospective, randomized, 2 arm, phase II clinical trial was conducted between February 2017 and April 2019 at the University of Miami, Miami, Florida, U.S.A. Patients were treated with MoreNova, a shockwave device developed by Hikkonu Ltd and marketed by DirexGroup. This device uses an electromagnetic generator designed to deliver “linear” shockwaves, that is, wave fronts that are geometrically-matched to the shape of the corpora and crura. Unlike other electromagnetic shockwave generators, this device does not apply a point-focuser, but instead uses the patented Large Area Shockwave Technology to simultaneously deliver shockwaves to whole segments of the corpora and crura. Compared to radial shockwaves, the focused shockwave has a much shorter pulse duration, deeper penetration depth, and has its effect at the cellular rather than superficial tissue level. The treatment device can target a focused area with greater pressure.